RYZ401 / BMS - LARVOL DELTA

A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 (225Ac), in patients with neuroendocrine tumors (NETs) and other solid tumors expressing somatostatin receptors (SSTRs). (ASCO-GI 2026) - P1 | "Funded by RayzeBio Clinical Trial Registration Number: NCT07165132 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • First-in-human • P1 data • Gastrointestinal Cancer • Oncology • Solid Tumor • SSTR

Novel SSTR2 RPT agent RYZ401 demonstrates significant improvement in Biodistribution and Efficacy compared to DOTATATE (EANM 2025) - No abstract available

Clinical • Oncology • SSTR2

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. (clinicaltrials.gov) - P1 | N=104 | Not yet recruiting | Sponsor: RayzeBio, Inc.

New P1 trial • Carcinoid Tumor • Endocrine Cancer • Neuroendocrine Tumor • Solid Tumor